Completed PHASE1 INTERVENTIONAL 2-arm NCT00653419

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions

Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Par and Bristol-Myers Squibb (Buspar) 15 mg Buspirone HCl Tablets in Healthy Adult Males Under Fasting Conditions Following Administration of a 30 mg Dose

Sponsor: Par Pharmaceutical, Inc.

Conditions To Determine Bioequivalence Under Fasting Conditions

Interventions Buspar buspirone HCl

Updated 6 times since 2017 Last updated: Apr 1, 2008 Started: Jun 30, 1998 Primary completion: Sep 30, 1998 Completion: Sep 30, 1998

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on To Determine Bioequivalence Under Fasting Conditions, this trial is completed. The trial is conducted by Par Pharmaceutical, Inc. and has accumulated 6 data snapshots since 1998. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2017 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Par Pharmaceutical, Inc.
Phoenix International Life Sciences, Inc.

Data source: Par Pharmaceutical, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint-Laurent, Canada